Marker Therapeutics Announces $16.1 Million Private Placement
19. Dezember 2024 08:06 ET
|
Marker Therapeutics
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
19. Dezember 2024 08:05 ET
|
Marker Therapeutics
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well...
Refractory Follicular Lymphoma Diagnostics Market Trends and Forecasts to 2029 - The Rise of Liquid Biopsy
17. Dezember 2024 14:13 ET
|
Research and Markets
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Refractory Follicular Lymphoma Diagnostics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to...
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
17. Dezember 2024 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
17. Dezember 2024 07:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
10. Dezember 2024 08:30 ET
|
Marker Therapeutics
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
26. November 2024 11:00 ET
|
Marker Therapeutics
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
14. November 2024 16:30 ET
|
Marker Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
14. August 2024 16:30 ET
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...